Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0TG1V
|
|||
Drug Name |
BDBM50177012
|
|||
Synonyms |
CHEMBL3814153; SCHEMBL17519222; BDBM50177012
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Structure |
Download2D MOL |
|||
Formula |
C19H22F4N4O2S
|
|||
Canonical SMILES |
CC(C)C1CN(CCN1C2=NC=CC(=N2)C(F)(F)F)C3=CC(=C(C=C3)F)S(=O)(=O)C
|
|||
InChI |
1S/C19H22F4N4O2S/c1-12(2)15-11-26(13-4-5-14(20)16(10-13)30(3,28)29)8-9-27(15)18-24-7-6-17(25-18)19(21,22)23/h4-7,10,12,15H,8-9,11H2,1-3H3/t15-/m0/s1
|
|||
InChIKey |
YTEDTWJJQBCOTI-HNNXBMFYSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Oxysterols receptor LXR-alpha (NR1H3) | Target Info | Inhibitor | [1] |
Target's Patent Info | Oxysterols receptor LXR-alpha (NR1H3) | Target's Patent Info | [1] | |
KEGG Pathway | PPAR signaling pathway | |||
Non-alcoholic fatty liver disease (NAFLD) | ||||
Hepatitis C | ||||
Pathway Interaction Database | RXR and RAR heterodimerization with other nuclear receptor | |||
WikiPathways | Nuclear Receptors in Lipid Metabolism and Toxicity | |||
Nuclear Receptors Meta-Pathway | ||||
PPAR Alpha Pathway | ||||
Liver X Receptor Pathway | ||||
Adipogenesis | ||||
SREBF and miR33 in cholesterol and lipid homeostasis | ||||
Nuclear Receptors |
References | Top | |||
---|---|---|---|---|
REF 1 | Piperazine derivatives as liver X receptor modulators. US10144715. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.